Pfizer and BioNTech jointly developed the Covid-19 vaccine. Credit: Jimmy Baikovicius / Flickr (Creative Commons).

Pfizer and BioNTech have submitted an application seeking Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a 10µg booster dose of their Covid-19 vaccine in children aged five to 11 years.

Based on the messenger ribonucleic acid (mRNA) technology of BioNTech, the vaccine was developed jointly by the companies.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The vaccine previously obtained FDA EUA for active immunisation for preventing Covid-19 in individuals aged five years and above. 

 The latest submission comprised findings from the Phase II/III clinical trial of the booster vaccine dose in children aged five to 11 years.

This booster dose was administered nearly six months following the second dose of the 10µg two-dose vaccine regiment.

See Also:

Results from the trial showed that the booster vaccine offered a robust immune response in subjects of this age group without any new safety signals. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

By submitting these findings, Pfizer and BioNTech intend to seek authorisation from the European Medicines Agency (EMA) and other regulatory authorities globally soon. 

The companies announced plans to assess a third 3µg dose of the vaccine administered a minimum of two months following the second dose in children aged under five years and a third 10µg dose in those aged five to below 12 years, in December last year. 

Findings from the trial underway in children aged six months to below five years are anticipated to be reported later in this quarter of the year.

In March this year, the FDA granted EUA for an additional booster dose of Pfizer and BioNTech’s Covid-19 vaccine for usage in adults of the age 50 years and above.

The second booster is indicated for people who have already received the first booster of any currently authorised Covid-19 vaccine.